Recent studies have evaluated the clinical effectiveness of the MiniMed 780G AHCL system in patients previously using advanced diabetes technologies, including continuous subcutaneous insulin infusion (CSII) or the CGMS or both combined to some degree in automated technologies [7,9-12]. This evidence concerns the gene INS and diabetes mellitus.